Read by QxMD icon Read

breast cancer therapy

Peng Zhang, Yiying Chen, Miaomiao Gong, Zhumei Zhuang, Yueyue Wang, Lin Mu, Tianjiao Wang, Jinjin Pan, Yanan Liu, Jianming Xu, Rui Liang, Yuhui Yuan
BACKGROUND/AIMS: HER2 has been implicated in mammary tumorigenesis as well as aggressive tumor growth and metastasis. Its overexpression is related to a poor prognosis and chemoresistance in breast cancer patients. Although Grb2-associated binding protein 2 (Gab2) is important in the development and progression of human cancer, its effects and mechanisms in HER2-overexpressing breast cancer are unclear. METHODS: Clone formation and MTT assays were used to examine cell proliferation...
October 16, 2018: Cellular Physiology and Biochemistry
Angeles C Tecalco-Cruz, Josue O Ramirez-Jarquin, Eduardo Cruz-Ramos
More than 70% of all breast cancer cases are estrogen receptor alpha-positive (ERα). ERα is a member of the nuclear receptor family, and its activity is implicated in the gene transcription linked to the proliferation of breast cancer cells, as well as in extranuclear signaling pathways related to the development of resistance to endocrine therapy. Several protein-protein interactions and post-translational modifications of ERα represent critical mechanisms that modulate its activity...
October 15, 2018: Current Drug Targets
Ruth Plummer, Henk M Verheul, Filip Y F L De Vos, Karin Leunen, L Rhoda Molife, Christian Rolfo, Peter Grundtvig-Sørensen, Jacques De Grève, Sylvie Rottey, Guy Jerusalem, Antoine Italiano, James Spicer, Luc Dirix, Carsten Goessl, Joseph Birkett, Stuart Spencer, Maria Learoyd, Christopher Bailey, Emma Dean
INTRODUCTION: The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer. This phase I study assessed the safety and pharmacokinetic (PK) profiles of olaparib combined with tamoxifen, anastrozole or letrozole in patients with advanced solid tumours. METHODS: During part A, PK profiles were assessed in three consecutive treatment periods: (1) olaparib (tablet) 300 mg bid, days 1-5 followed by a 4-day washout; (2) cohort 1, tamoxifen 60 mg loading dose qd days 10-13, 20 mg qd days 14-26; cohort 2, anastrozole 1 mg qd days 10-19; cohort 3, letrozole 2...
October 15, 2018: Advances in Therapy
Junji Tsurutani, Yukinori Sakata, Toshiyuki Matsuoka
BACKGROUND: Few studies have examined chemotherapy-induced peripheral neuropathy (CIPN) following the administration of eribulin as first- or second-line therapy in patients with breast cancer. We therefore assessed CIPN incidence by severity and risk factors for CIPN in patients treated with eribulin for HER2-negative inoperable or recurrent breast cancer, regardless of line therapy status. METHODS: This multicenter, prospective, post-marketing observational study enrolled patients from September 2014 in Japan and followed them for 2 years...
October 15, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
C Liedtke, Hans-Christian Kolberg, L Kerschke, D Görlich, I Bauerfeind, T Fehm, B Fleige, G Helms, A Lebeau, A Stäbler, S Schmatloch, M Hausschild, L Schwentner, Gunter von Minckwitz, S Loibl, M Untch, T Kühn
Optimization of axillary staging among patients converting from clinically node-positive disease to clinically node-negative disease through primary systemic therapy is needed. We aimed at developing a nomogram predicting the probability of positive axillary status after chemotherapy based on clinical/pathological parameters. Patients from study arm C of the SENTINA trial were included. Univariable/multivariable analyses were performed for 13 clinical/pathological parameters to predict a positive pathological axillary status after chemotherapy using logistic regression models...
October 15, 2018: Clinical & Experimental Metastasis
Talal Hilal, Bhavika K Patel
No abstract text is available yet for this article.
October 15, 2018: Annals of Surgical Oncology
Peter A Fasching, Andreas D Hartkopf, Paul Gass, Lothar Häberle, Leyla Akpolat-Basci, Alexander Hein, Bernhard Volz, Florin-Andrei Taran, Naiba Nabieva, Birgit Pott, Friedrich Overkamp, Hanna Einarson, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Wolfgang Janni, Tanja N Fehm, Andreas Schneeweiss, Michael Untch, Dirk Pott, Michael P Lux, Thomas Geyer, Cornelia Liedtke, Harald Seeger, Sarah Wetzig, Arndt Hartmann, Rüdiger Schulz-Wendtland, Erik Belleville, Diethelm Wallwiener, Matthias W Beckmann, Sara Y Brucker, Hans-Christian Kolberg
PURPOSE: Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world validation of these results from prospective randomized trials. METHODS: In a retrospective analysis conducted in the PRAEGNANT network, patients were eligible for inclusion if they had either received neoadjuvant therapy with CTX/TZM or chemotherapy, trastuzumab, and pertuzumab (CTX/TZM/PTZ) and subsequently underwent surgery for their primary breast cancer...
October 15, 2018: Breast Cancer Research and Treatment
Hye Won Hwang, Hera Jung, Jiyeon Hyeon, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong-Han Yu, Se Kyung Lee, Misun Choi, Soo Youn Cho, Eun Yoon Cho
PURPOSE: The value of tumor-infiltrating lymphocytes (TILs) for prediction of pathologic complete response (pCR) in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) has received increasing attention. In human epidermal growth factor receptor 2 (HER2)-positive BC, advances in HER2-targeted therapy have not yet clarified the clinical implications of pre-NAC TILs. Likewise, the prognostic role of TILs for long-term survival is not well established. METHODS: Pre- and post-NAC TIL levels were evaluated in 248 pair-matched pre-NAC biopsy and post-NAC resection samples, and analyzed for predictive and prognostic significance with other clinicopathologic parameters...
October 15, 2018: Breast Cancer Research and Treatment
Yongmei Zhao, Nicholas L Fletcher, Tianqing Liu, Anna C Gemmell, Zachary H Houston, Idriss Blakey, Kristofer J Thurecht
Targeted nanomedicines offer many advantages over macromolecular therapeutics that rely only on passive accumulation within the tumour environment. The aim of this work was to investigate the in vivo anticancer efficiency of polymeric nanomedicines that were conjugated with peptide aptamers that show high affinity for receptors on many cancer cells. In order to assess the ability for the nanomedicine to treat cancer and investigate how structure affected the behavior of the nanomedicine, three imaging modalities were utilized, including in vivo optical imaging, multispectral optoacoustic tomography (MSOT) and ex vivo confocal microscopy...
2018: Nanotheranostics
Mattias Hoffner, Karin Ohlin, Barbro Svensson, Jonas Manjer, Emma Hansson, Thomas Troëng, Håkan Brorson
Background: Arm lymphedema is a well-recognized complication after breast cancer surgery that negatively impacts patients' quality of life, both physiologically and psychologically. Lymph stasis and inflammation result in excess formation of adipose tissue, which makes removal of the deposited subcutaneous fat necessary to eliminate the excess volume. Liposuction, combined with postoperative controlled compression therapy (CCT), is the only treatment that gives complete reduction of the excess volume...
August 2018: Plastic and Reconstructive Surgery. Global Open
Huiping Li, Yaping Xu, Fangyuan Zhao, Guohong Song, Hope S Rugo, Yan Zhang, Ling Yang, Xiaoran Liu, Bin Shao, Liang Yang, Yaxin Liu, Ran Ran, Ruyan Zhang, Yanfang Guan, Lianpeng Chang, Xin Yi
Through next generation sequencing, this study evaluated the circulating tumor DNA (ctDNA) of advanced breast cancer patients to prospectively explore the relationship between specific DNA mutations and prognosis as well as therapeutic decision making. The target region covered 1021 gene totally. Clinical characteristics, treatment and outcome data were collected. We analyzed progression-free survival (PFS) from first-line therapy and overall survival (OS), and found that their endpoints were correlated with observed gene mutations...
2018: American Journal of Cancer Research
Bin Shao, Chia-Wei Li, Seung-Oe Lim, Linlin Sun, Yun-Ju Lai, Junwei Hou, Chunxiao Liu, Chiung-Wen Chang, Yufan Qiu, Jung-Mao Hsu, Li-Chuan Chan, Zhengyu Zha, Huiping Li, Mien-Chie Hung
Triple-negative breast cancer (TNBC), the most difficult-to-treat breast cancer subtype, lacks well-defined molecular targets. TNBC has increased programmed death-ligand 1 (PD-L1) expression, and its immunosuppressive nature makes it suitable for immune checkpoint blockade therapy. However, the response rate of TNBC to anti-PD-L1 or anti-programmed cell death protein 1 (PD-1) therapy remains unsatisfactory, as only 10-20% of TNBC patients have a partial response. Glycosylated PD-L1, the functional form of PD-L1, is required for PD-L1-PD-1 interaction...
2018: American Journal of Cancer Research
Tasaduq H Wani, Sreeraj Surendran, Vishnu S Mishra, Jaya Chaturvedi, Goutam Chowdhury, Anindita Chakrabarty
Sepantronium bromide (YM155), originally developed against the anti-apoptotic protein survivin, performed exceptionally well in pre-clinical and phase I clinical trials. However, in phase II trials of several cancer types including breast cancer it performed poorly. Additionally, no definitive correlation between survivin level and response to therapy was found. In an attempt to understand the true reason of the late-stage failure of this promising drug, we developed YM155-resistant MCF-7 breast cancer cell line and characterized side-by-side with the drug-naïve parental cell line...
September 11, 2018: Oncotarget
Joseph A Bovi
The incidence of brain metastases is projected to rise because survival rates of lung cancer, breast cancer, and melanoma continue to improve (1). The brain is being identified as a sanctuary site for harboring metastases despite excellent control of extracranial disease. This is thought to occur because the drug therapies that control extracranial disease have limited central nervous system (CNS) penetration. The development of brain metastases is a devastating diagnosis affecting both quality of life (QOL) and survival...
2018: Frontiers in Neurology
Sharon W Goodill
This review offers a discussion of the state of dance/movement therapy (DMT), research with people living with cancer. The vast majority of extant studies published in the English language are with women with breast cancer. An examination of challenges facing DMT researchers in this area is provided, and recommendations for research foci, and priorities are outlined. These include qualitative syntheses, integration of implementation evidence with qualitative synthesis, and formal process evaluation studies.
2018: Frontiers in Psychology
Yi Ding, Chang Gong, De Huang, Rui Chen, Pinpin Sui, Kevin H Lin, Gehao Liang, Lifeng Yuan, Handan Xiang, Junying Chen, Tao Yin, Peter B Alexander, Qian-Fei Wang, Er-Wei Song, Qi-Jing Li, Kris C Wood, Xiao-Fan Wang
Intrinsic resistance to anti-HER2 therapy in breast cancer remains an obstacle in the clinic, limiting its efficacy. However, the biological basis for intrinsic resistance is poorly understood. Here we performed a CRISPR/Cas9-mediated loss-of-function genetic profiling and identified TALDO1, which encodes the rate-limiting transaldolase (TA) enzyme in the non-oxidative pentose phosphate pathway, as essential for cellular survival following pharmacological HER2 blockade. Suppression of TA increases cell susceptibility to HER2 inhibition in two intrinsically resistant breast cancer cell lines with HER2 amplification...
October 15, 2018: Nature Communications
Cesar A Santa-Maria, Rita Nanda
Initial studies investigating single-agent activity of immune checkpoint inhibitors (ICIs) serve as proof of principle that harnessing the immune system can have anticancer activity in a variety of human malignancies. Although breast cancer was historically believed to be immunogenically silent, early studies indicate overall response rates with ICIs are similar to those observed with many other solid malignancies. Overall response rates in advanced breast cancer are low, but the responses are remarkably durable...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
Leila Family, Yanli Li, Lie Hong Chen, John H Page, Zandra K Klippel, Chun Chao
Background: Previously identified patient-level risk factors for chemotherapy-induced febrile neutropenia (FN) indicate several potential underlying pathogenic mechanisms, including bone marrow suppression, impaired neutrophil function, or disturbances of barrier function. This study evaluated whether additional clinical characteristics related to these pathogenic mechanisms were risk factors for FN. Patients and Methods: The study population included patients diagnosed with non-Hodgkin's lymphoma or breast, lung, colorectal, ovarian, or gastric cancer between 2000 and 2009 at Kaiser Permanente Southern California and treated with myelosuppressive chemotherapy...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
Bence Dorogi, Bence Bukovszky, Tamás Mátrai, Ákos Sávolt, Csaba Polgár, Péter Kelemen, Tibor Kovács, Ferenc Rényi-Vámos, Gabriella Ivády, Eszter Kovács, Melinda Téglás, Miklós Kásler, Zoltán Mátrai
INTRODUCTION: The aims of this study were to investigate the correlation between lymphatic drainage and the sentinel lymph node (SLN) status of the subregions in the context of the clinic-pathological parameters of the tumour and the coverage of the axillary volumes by standard and high tangential fields (STgF and HTgF) for whole breast radiotherapy and axillary reverse mapping (ARM). PATIENTS AND METHODS: 933 women with early breast cancer and clinically negative axillary status underwent breast surgery and SLN biopsy followed by axillary lymph node dissection in SLN-positive cases...
October 7, 2018: European Journal of Surgical Oncology
Ji Hyeon Joo, Su Ssan Kim, Byung Ho Son, Seung Do Ahn, Jin Hong Jung, Eun Kyung Choi, Sei Hyun Ahn, Jong Won Lee, Hee Jeong Kim, Beom Seok Ko
Purpose: Axillary lymph node dissection (ALND) may be avoidable for breast cancer patients with 1-2 positive lymph nodes (LN) after breast-conserving therapy. However, the effects of ALND after mastectomy remain unclear because radiation is not routinely used. Herein, we compared the benefits of post-mastectomy ALND versus sentinel node biopsy (SNB) alone for breast cancer patients with 1-3 metastatic LNs. Materials and Methods: A total of 1,697 patients with pN1 disease who underwent mastectomy during 2000-2015 were identified from an institutional database...
October 16, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"